What is Antidote?
Established in 2010, Antidote operates at the intersection of technology and clinical research. The company specializes in precision recruitment, a methodology designed to optimize the patient-to-trial matching process. By integrating deep domain expertise with a robust partner network, Antidote addresses the persistent challenges of patient engagement in medical studies. Its platform serves as a vital conduit for pharmaceutical companies and research organizations, facilitating faster, more inclusive, and more effective clinical trial outcomes. With a dual presence in the US and UK, the company maintains a unique market position, balancing digital scalability with personalized site services to improve the overall quality of medical research.
How much funding has Antidote raised?
Antidote has raised a total of $52.1M across 5 funding rounds:
Other Financing Round
$1.2M
Series A
$3.2M
Series B
$13.5M
Private Equity
$11M
Unspecified
$23.2M
Other Financing Round (2011): $1.2M with participation from Amadeus Capital Partners
Series A (2013): $3.2M led by Octopus Ventures and Amadeus Capital Partners
Series B (2015): $13.5M supported by Octopus Ventures and Amadeus Capital Partners
Private Equity (2017): $11M featuring Octopus Ventures, Smedvig Capital, and Merck Global Health Innovation Fund
Unspecified (2021): $23.2M backed by LBO France
Key Investors in Antidote
Octopus Ventures
Octopus Ventures is a leading UK-based investment firm specializing in tax-efficient vehicles and venture capital, providing significant support to high-growth companies across various sectors.
Amadeus Capital Partners
Amadeus Capital Partners is a global technology venture capital firm that focuses on scaling high-growth businesses in sectors including digital health, artificial intelligence, and deep tech.
Merck Global Health Innovation Fund
The Merck Global Health Innovation Fund is the strategic investment arm of the global healthcare giant Merck & Co., focusing on innovative solutions in medicine, vaccines, and digital health.
What's next for Antidote?
With the recent major strategic investment, Antidote is well-positioned to expand its technological footprint and deepen its influence within the clinical research landscape. The company is likely to focus on enhancing its data-driven recruitment algorithms and broadening its network of diverse partners to address the increasing complexity of modern clinical trials. As the digital health market continues to mature, Antidote's ability to maintain its high-quality patient engagement standards will be paramount. The firm is expected to leverage this capital to drive further innovation in patient-centric services, potentially exploring new therapeutic areas and strengthening its international operational capacity to meet the growing demand for efficient, technology-enabled medical research solutions.
See full Antidote company page
